These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 36091104)
1. RPP40 is a prognostic biomarker and correlated with tumor microenvironment in uterine corpus endometrial carcinoma. Tang J; Tian X; Min J; Hu M; Hong L Front Oncol; 2022; 12():957472. PubMed ID: 36091104 [TBL] [Abstract][Full Text] [Related]
2. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma. Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290 [TBL] [Abstract][Full Text] [Related]
3. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis. Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189 [TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma. Chen Y Front Genet; 2022; 13():912037. PubMed ID: 35937995 [No Abstract] [Full Text] [Related]
5. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma. Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000 [No Abstract] [Full Text] [Related]
6. miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma. Lu X; Jing L; Liu S; Wang H; Chen B Int J Endocrinol; 2022; 2022():5006123. PubMed ID: 35719192 [TBL] [Abstract][Full Text] [Related]
7. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. Wang N; Zhu L; Wang L; Shen Z; Huang X Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736 [TBL] [Abstract][Full Text] [Related]
8. Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118 [TBL] [Abstract][Full Text] [Related]
9. Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma. Li D; Zhang J; Wu L; Yang X; Chen Z; Yuan J Cancer Manag Res; 2021; 13():7311-7323. PubMed ID: 34584457 [TBL] [Abstract][Full Text] [Related]
10. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma. Wang Z; Xing L; Huang Y; Han P Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive bioinformatic analyses of lncRNA-mediated ceRNA network for uterine corpus endometrial carcinoma. Cai Y; Cui J; Wang Z; Wu H Transl Cancer Res; 2022 Jul; 11(7):1994-2012. PubMed ID: 35966302 [TBL] [Abstract][Full Text] [Related]
12. Construction of a prognostic model of luteolin for endometrial carcinoma. Zhao J; Jiao W; Sui X; Zou J; Wang J; Lin Z Am J Transl Res; 2023; 15(3):2122-2139. PubMed ID: 37056832 [TBL] [Abstract][Full Text] [Related]
13. Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer. Li J; Xu W; Zhu Y Oncol Lett; 2020 Nov; 20(5):255. PubMed ID: 32994818 [TBL] [Abstract][Full Text] [Related]
14. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer. Liu J; Ji C; Wang Y; Zhang C; Zhu H Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of zinc finger DHHC-type containing 1 is associated with poor prognosis and cancer cell growth and metastasis in uterine corpus endometrial carcinoma. Jiang N; Li D; Han Y; Luo ZG; Liu LB Aging (Albany NY); 2024 Jun; 16(11):9784-9812. PubMed ID: 38848146 [TBL] [Abstract][Full Text] [Related]
16. Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma. Gu H; Song J; Chen Y; Wang Y; Tan X; Zhao H Front Oncol; 2022; 12():923641. PubMed ID: 35719911 [TBL] [Abstract][Full Text] [Related]
17. SPC25 Functions as a Prognostic-Related Biomarker, and Its High Expression Correlates with Tumor Immune Infiltration and UCEC Progression. Liao LX; Zhang M; Xu X; Zhang S; Guo YZ Front Biosci (Landmark Ed); 2024 Feb; 29(2):69. PubMed ID: 38420826 [TBL] [Abstract][Full Text] [Related]
18. TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification. Miao L; Chen B; Jing L; Zeng T; Chen Y Recent Pat Anticancer Drug Discov; 2024 Jan; ():. PubMed ID: 38305309 [TBL] [Abstract][Full Text] [Related]
19. Elevated Expression of Gamma-Glutamyl Hydrolase Is Associated With Poor Prognosis and Altered Immune Signature in Uterine Corpus Endometrial Carcinoma. Yu C; Qi H; Zhang Y; Zhao W; Wu G Front Genet; 2021; 12():764194. PubMed ID: 35082830 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of ESRRA in Endometrial Cancer. Wang S; Huo X Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]